open access

Vol 49, No 4 (2018)
Original Research Article/Praca Oryginalna
Published online: 2018-12-31
Submitted: 2018-07-18
Get Citation

Plerixafor for patients who fail cytokine-or chemotherapy-based stem cell mobilization: Results of a prospective study by the Polish Lymphoma Research Group (PLRG)

Sebastian Giebel, Sylwia Oborska, Joanna Romejko-Jarosinska, Jarosław Dybko, Joanna Mańko, Joanna Sawczuk-Chabin, Agata Szymańska, Wojciech Legieć, Anna Czyż, Magdalena Maruszak, Maria Saduś-Wojciechowska, Joanna Drozd-Sokołowska, Paweł Steckiewicz, Anna Ejduk, Ewa Paszkiewicz-Kozik, Tomasz Ogórka, Michał Osowiecki, Łukasz Targoński, Michał Taszner
DOI: 10.2478/ahp-2018-0027
·
Acta Haematol Pol 2018;49(4):234-239.

open access

Vol 49, No 4 (2018)
Original Research Article/Praca Oryginalna
Published online: 2018-12-31
Submitted: 2018-07-18

Abstract

Autologous hematopoietic stem cell transplantation (autoHSCT) requires collection of sufficient number of hematopoietic stem cells. The goal of this study was to evaluate efficacy of plerixafor used in patients with lymphoid malignancies failing conventional stem cell mobilization.

This was a prospective, non-interventional study. All consecutive patients (n = 109) treated with plerixafor in 11 centers were reported. The drug was used either in case of previous mobilization failure (n = 67) or interventionally, in case of insufficient CD34 cell output during current mobilization (n = 42). Successful mobilization was defined as resulting in collection of ≥ 2 × 10 CD34 cells/kg for single autoHSCT or ≥ 4 × 10 CD34 cells/kg for double procedure.

The overall rate of successful mobilization was 55% (55% for single and 56% for double autoHSCT). The median total number of collected CD34 cells/kg was 2.4 (range, 0-11.5) for patients intended for a single transplantation while 4.0 (0.6-16.9) for double procedure. The number of circulating CD34 cells increased after the use of plerixafor regardless of baseline values. The median fold increase was 3.3 (0.3-155). Data from this observational study confirm high efficacy of plerixafor used in routine clinical practice as salvage for patients with lymphoid malignancies failing conventional stem cell mobilization.

Abstract

Autologous hematopoietic stem cell transplantation (autoHSCT) requires collection of sufficient number of hematopoietic stem cells. The goal of this study was to evaluate efficacy of plerixafor used in patients with lymphoid malignancies failing conventional stem cell mobilization.

This was a prospective, non-interventional study. All consecutive patients (n = 109) treated with plerixafor in 11 centers were reported. The drug was used either in case of previous mobilization failure (n = 67) or interventionally, in case of insufficient CD34 cell output during current mobilization (n = 42). Successful mobilization was defined as resulting in collection of ≥ 2 × 10 CD34 cells/kg for single autoHSCT or ≥ 4 × 10 CD34 cells/kg for double procedure.

The overall rate of successful mobilization was 55% (55% for single and 56% for double autoHSCT). The median total number of collected CD34 cells/kg was 2.4 (range, 0-11.5) for patients intended for a single transplantation while 4.0 (0.6-16.9) for double procedure. The number of circulating CD34 cells increased after the use of plerixafor regardless of baseline values. The median fold increase was 3.3 (0.3-155). Data from this observational study confirm high efficacy of plerixafor used in routine clinical practice as salvage for patients with lymphoid malignancies failing conventional stem cell mobilization.

Get Citation

Keywords

plerixafor; stem cell mobilization; multiple myeloma; Hodgkin lymphoma; non-Hodgkin lymphoma

About this article
Title

Plerixafor for patients who fail cytokine-or chemotherapy-based stem cell mobilization: Results of a prospective study by the Polish Lymphoma Research Group (PLRG)

Journal

Acta Haematologica Polonica

Issue

Vol 49, No 4 (2018)

Pages

234-239

Published online

2018-12-31

DOI

10.2478/ahp-2018-0027

Bibliographic record

Acta Haematol Pol 2018;49(4):234-239.

Keywords

plerixafor
stem cell mobilization
multiple myeloma
Hodgkin lymphoma
non-Hodgkin lymphoma

Authors

Sebastian Giebel
Sylwia Oborska
Joanna Romejko-Jarosinska
Jarosław Dybko
Joanna Mańko
Joanna Sawczuk-Chabin
Agata Szymańska
Wojciech Legieć
Anna Czyż
Magdalena Maruszak
Maria Saduś-Wojciechowska
Joanna Drozd-Sokołowska
Paweł Steckiewicz
Anna Ejduk
Ewa Paszkiewicz-Kozik
Tomasz Ogórka
Michał Osowiecki
Łukasz Targoński
Michał Taszner

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl